The October 6 special meeting vote on the three proposals will determine whether the board reconstitution proceeds. Approval would trigger a change of control under Nasdaq rules and likely lead to a fully new board with Orphai-aligned directors. Monitor the vote outcome and any subsequent 8-K filings for final board composition and any further governance changes.
Price Chart
Executive Summary
Quince Therapeutics filed a DEFA14A supplement to its proxy statement, announcing that three directors (June Bray, David Lamond, Christopher Senner) have tendered conditional resignations effective after the October 6, 2026 special meeting, contingent on stockholder approval of three proposals (Conversion Proposal, Minimum Price Proposal, Authorized Shares Proposal). Four new directors (Catherine Bonuccelli, Leone Patterson, James Valentine, Drayton Wise) have been conditionally appointed to replace them, with committee assignments disclosed. This board reconstitution is tied to the Orphai Therapeutics acquisition and the related stock issuance proposals, signaling a planned change of control and governance overhaul.
Key Financial Metrics
Key Facts
- Three directors (June Bray, David Lamond, Christopher Senner) tendered conditional resignations on September 30, 2026, effective two business days after the October 6, 2026 special meeting, contingent on stockholder approval of three proposals.
- Four new directors (Catherine Bonuccelli, Leone Patterson, James Valentine, Drayton Wise) were conditionally appointed on October 1, 2026, effective at the same time as the resignations.
- The resignations and appointments are tied to stockholder approval of the Conversion Proposal, Minimum Price Proposal, and Authorized Shares Proposal, which relate to the Orphai Therapeutics acquisition and issuance of shares upon conversion of Series C Preferred Stock and warrants.
- The new board composition includes Leone Patterson as chair of both Audit and Compensation Committees, James Valentine as chair of Nominating and Corporate Governance Committee, and Catherine Bonuccelli and Drayton Wise as committee members.
- The filing supplements the August 25, 2026 definitive proxy statement; the board's recommendation on all proposals remains unchanged.
Financial Impact
No financial figures disclosed in this filing. The proposals involve issuance of shares upon conversion of Series C Preferred Stock and exercise of warrants, which could result in significant dilution if approved, but no specific dollar amounts are provided.
Risk Factors
- If stockholders do not approve the proposals, the resignations and appointments will not take effect, leaving the current board in place and potentially creating uncertainty around the Orphai acquisition integration.
- The conditional nature of the resignations and appointments means the outcome is binary — approval leads to a new board, rejection leaves the status quo, which could create governance instability.
- The issuance of shares upon conversion of Series C Preferred Stock and exercise of warrants could result in substantial dilution to existing common stockholders if the proposals are approved.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-411262 |
| Document: 0001193125-26-411262-index-headers.html | 0001193125-26-411262 |
| Document: 0001193125-26-411262-index.html | 0001193125-26-411262 |
| Document: 0001193125-26-411262.txt | 0001193125-26-411262 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $31.73 $32.03 | ▲ +0.95% | ▲ +2.91% | $32.47 (+2.35%) |
Oct 2, 2026 25d ago | DEFA14A | $29.20 $31.73 | ▲ +8.66% | ▲ +7.50% | $32.47 (+11.22%) |
Oct 2, 2026 25d ago | 8-K | $29.20 $31.73 | ▲ +8.66% | ▲ +7.50% | $32.47 (+11.22%) |
Sep 4, 2026 7w ago | 8-K | $31.32 $28.59 | ▲ +8.72% | ▲ +7.51% | $32.47 (−3.69%) |
Aug 25, 2026 9w ago | EFFECT | $30.93 $32.11 | ▼ −3.82% | ▼ −4.35% | $32.47 (−5.00%) |
Aug 14, 2026 10w ago | 8-K | $31.34 | awaiting T+5 | — | $32.47 (+3.62%) |
Aug 14, 2026 10w ago | Press Release | $31.34 | awaiting T+5 | — | $32.47 (+3.62%) |
Aug 5, 2026 11w ago | S-3/A | $28.88 $31.26 | ▲ +8.24% | ▲ +7.89% | $32.47 (+12.45%) |
Jun 11, 2026 19w ago | 3 | $0.9337 $0.9276 | ▼ −0.65% | ▼ −1.01% | $32.47 (+3378.10%) |
May 18, 2026 23w ago | 8-K | $19.90 $24.00 | ▲ +20.60% | ▲ +18.99% | $32.47 (+63.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers